Loading clinical trials...
Loading clinical trials...
A Phase 1b/2, Open-label Dose Escalation With Expansion Study of GB5121 in Adult Patients With Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma, With a Phase 2 Open-label Single Dose Level Study of GB5121 in Adult Patients With Relapsed/ Refractory Primary Central Nervous System Lymphoma
Conditions
Interventions
GB5121
Locations
16
United States
Mayo Clinic
Phoenix, Arizona, United States
Mayo Clinic
Jacksonville, Florida, United States
Mayo Clinic
Rochester, Minnesota, United States
Memorial Sloan Kettering Cancer Center Main Campus
New York, New York, United States
Peter MacCallum Cancer Center
Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Start Date
May 24, 2022
Primary Completion Date
May 11, 2023
Completion Date
May 11, 2023
Last Updated
June 13, 2023
NCT06931652
NCT05098613
NCT05036564
NCT05926427
NCT04006561
NCT04464200
Lead Sponsor
GB005, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions